- Home
- PHI vs APLS Comparison
PHI vs APLS Comparison
Compare PHI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHI
- APLS
- Stock Information
- Founded
- PHI 1928
- APLS 2009
- Country
- PHI Philippines
- APLS United States
- Employees
- PHI N/A
- APLS N/A
- Industry
- PHI Telecommunications Equipment
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- PHI Telecommunications
- APLS Health Care
- Exchange
- PHI Nasdaq
- APLS Nasdaq
- Market Cap
- PHI 4.1B
- APLS 3.5B
- IPO Year
- PHI 1953
- APLS 2017
- Fundamental
- Price
- PHI $19.07
- APLS $24.92
- Analyst Decision
- PHI Hold
- APLS Buy
- Analyst Count
- PHI 1
- APLS 20
- Target Price
- PHI N/A
- APLS $33.47
- AVG Volume (30 Days)
- PHI 138.2K
- APLS 2.2M
- Earning Date
- PHI 11-11-2025
- APLS 11-04-2025
- Dividend Yield
- PHI 6.35%
- APLS N/A
- EPS Growth
- PHI 20.57
- APLS N/A
- EPS
- PHI 2.62
- APLS N/A
- Revenue
- PHI $3,879,170,293.00
- APLS $754,649,000.00
- Revenue This Year
- PHI $3.27
- APLS $22.11
- Revenue Next Year
- PHI $3.07
- APLS N/A
- P/E Ratio
- PHI $7.28
- APLS N/A
- Revenue Growth
- PHI 2.02
- APLS 20.02
- 52 Week Low
- PHI $18.61
- APLS $16.10
- 52 Week High
- PHI $27.73
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- PHI 37.27
- APLS 57.14
- Support Level
- PHI $18.69
- APLS $21.07
- Resistance Level
- PHI $19.08
- APLS $23.50
- Average True Range (ATR)
- PHI 0.34
- APLS 0.78
- MACD
- PHI 0.08
- APLS 0.18
- Stochastic Oscillator
- PHI 29.28
- APLS 99.10
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.